PCM
TCRR

Penserra Capital Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Penserra Capital Management’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-875
Closed -$7K – 1614
2021
Q3 		$7K Buy
875
+5
+0.6% +$71 ﹤0.01% 1397
2021
Q2 		$14K Buy
870
+15
+2% +$303 ﹤0.01% 1246
2021
Q1 		$18K Buy
855
+90
+12% +$2.45K ﹤0.01% 984
2020
Q4 		$23K Buy
+765
New +$19.3K ﹤0.01% 833

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Penserra Capital Management's TCRR Position: Q4 2021 in Review

Penserra Capital Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2021, closing a stake of 875 shares — an estimated $7K sold.

Penserra Capital Management first reported a position in TCRR in Q4 2020 and held it in 4 quarters. The position peaked at $23K in Q4 2020. 122 funds tracked by Wall St. Rank hold TCRR as of Q4 2021.

  • Penserra Capital Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 875 TCR2 Therapeutics Inc. Common Stock shares in Q4 2021, an estimated $7K.
  • Penserra Capital Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's TCR2 Therapeutics Inc. Common Stock position peaked at $23K in Q4 2020.
  • 122 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.